Literature DB >> 19739695

Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study.

Feifei Wei1, A Lauren Crain, Robin R Whitebird, Olga V Godlevsky, Patrick J O'Connor.   

Abstract

Antidepressant use in US adults increased 3-fold from 2.5% in 1988-94 to 8.1% in 1999-2002, based on National Health and Nutrition Examination Surveys. As the use of antidepressants increases, a comprehensive understanding of the potential health risks that may be associated with their use becomes increasingly important. This study evaluated the effects of paroxetine and sertraline on low-density lipoprotein cholesterol (LDL-C). An observational cohort study (1997-2004) of adults who had taken paroxetine or sertraline for at least 60 continuous days and had > or =2 LDL-C values measured during the study period, one while taking and one while not taking paroxetine or sertraline. A total of 13 634 LDL-C values clustered within 2682 patients were studied. We conducted mixed model regression analyses to quantify the relationship between antidepressant use and LDL-C values. The number of days taking paroxetine (beta = 0.0045; 95% CI 0.0018, 0.0073) and sertraline (beta = 0.0074; 95% CI 0.0054, 0.0093) prior to the LDL-C test were related to higher LDL-C values, after accounting for age, sex, year LDL-C was tested, co-morbidity, depression and lipid medication. The number of days that had passed since exposure to paroxetine (beta = -0.0013; 95% CI -0.0020, -0.00061) or sertraline (beta = -0.00093; 95% CI -0.016, -0.00022) were related to lower LDL-C values. The significant interaction between exposure to an antidepressant and taking a lipid medication demonstrates that the increase in LDL-C values associated with antidepressant use is ameliorated among patients who were taking a lipid medication when LDL-C was measured. Our study showed that long-term use of paroxetine or sertraline may have a measurable adverse impact on cardiovascular risk in adults. Clinical strategies should be used to address cardiovascular risk while maintaining effective treatment of major depression. In light of these findings, attention to LDL-C values should accompany antidepressant use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19739695     DOI: 10.2165/11310840-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  28 in total

1.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

Review 2.  The treatment of neuropathic pain: antidepressants and opioids.

Authors:  C P Watson
Journal:  Clin J Pain       Date:  2000-06       Impact factor: 3.442

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

Authors:  R Davis; M I Wilde
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

5.  Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients.

Authors:  V Ricca; E Mannucci; M Di Bernardo; S M Rizzello; P L Cabras; C M Rotella
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

6.  Increased cholesterol levels during paroxetine administration in healthy men.

Authors:  Nathalie Lara; Glen B Baker; Stephen L Archer; Jean-Michel Le Mellédo
Journal:  J Clin Psychiatry       Date:  2003-12       Impact factor: 4.384

7.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

Authors:  M R Law; N J Wald; S G Thompson
Journal:  BMJ       Date:  1994-02-05

Review 8.  Painful peripheral neuropathy and its nonsurgical treatment.

Authors:  Gil I Wolfe; Jaya R Trivedi
Journal:  Muscle Nerve       Date:  2004-07       Impact factor: 3.217

Review 9.  Pharmacologic management part 1: better-studied neuropathic pain diseases.

Authors:  Misha-Miroslav Backonja; Jordi Serra
Journal:  Pain Med       Date:  2004-03       Impact factor: 3.750

10.  The effects of mirtazapine on plasma lipid profiles in healthy subjects.

Authors:  Linda M Nicholas; Amy L Ford; Sharon M Esposito; R David Ekstrom; Robert N Golden
Journal:  J Clin Psychiatry       Date:  2003-08       Impact factor: 4.384

View more
  7 in total

1.  Effects of long-term sertraline treatment and depression on coronary artery atherosclerosis in premenopausal female primates.

Authors:  Carol A Shively; Thomas C Register; Susan E Appt; Thomas B Clarkson
Journal:  Psychosom Med       Date:  2015-04       Impact factor: 4.312

Review 2.  The impact of treatment with selective serotonin reuptake inhibitors on primate cardiovascular disease, behavior, and neuroanatomy.

Authors:  Carol A Shively; Marnie Silverstein-Metzler; Jamie Justice; Stephanie L Willard
Journal:  Neurosci Biobehav Rev       Date:  2016-08-30       Impact factor: 8.989

3.  The effects of sertraline on blood lipids, glucose, insulin and HBA1C levels: A prospective clinical trial on depressive patients.

Authors:  Murat Kesim; Ahmet Tiryaki; Mine Kadioglu; Efnan Muci; Nuri Ihsan Kalyoncu; Ersin Yaris
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

4.  Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder.

Authors:  Katrine Kveli Fjukstad; Anne Engum; Stian Lydersen; Ingrid Dieset; Nils Eiel Steen; Ole A Andreassen; Olav Spigset
Journal:  J Clin Psychopharmacol       Date:  2016-12       Impact factor: 3.153

5.  Severe hypertriglyceridemia secondary to venlafaxine use in an older adult on dialysis -case report.

Authors:  Hsiang-Wen Lin; Cory A Simonavice; Chiung-Ray Lu; Wen-Ling Lin; Po-Lun Wu; Che-Yi Chou; Chun-Hui Liao; Hsieh-Yuan Lane
Journal:  BMC Health Serv Res       Date:  2017-04-13       Impact factor: 2.655

6.  Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial.

Authors:  Chieh-Hsin Lin; Shi-Heng Wang; Hsien-Yuan Lane
Journal:  Int J Neuropsychopharmacol       Date:  2022-08-04       Impact factor: 5.678

Review 7.  Off-Target Effects of Antidepressants on Vascular Function and Structure.

Authors:  Anna Dimoula; Dimitrios Fotellis; Evmorfia Aivalioti; Dimitrios Delialis; Alexia Polissidis; Raphael Patras; Nikolaos Kokras; Kimon Stamatelopoulos
Journal:  Biomedicines       Date:  2021-12-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.